Cargando…

EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation

BACKGROUND: Uveal melanoma (UM) is a rare eye tumor. There are two classes of UM, which can be discriminated by the chromosome 3 status or global mRNA expression profile. Metastatic progression is predominantly originated from class II tumors or from tumors showing loss of an entire chromosome 3 (mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Neumann, Lisa C, Weinhäusel, Andreas, Thomas, Stefanie, Horsthemke, Bernhard, Lohmann, Dietmar R, Zeschnigk, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175225/
https://www.ncbi.nlm.nih.gov/pubmed/21871071
http://dx.doi.org/10.1186/1471-2407-11-380
_version_ 1782212135181352960
author Neumann, Lisa C
Weinhäusel, Andreas
Thomas, Stefanie
Horsthemke, Bernhard
Lohmann, Dietmar R
Zeschnigk, Michael
author_facet Neumann, Lisa C
Weinhäusel, Andreas
Thomas, Stefanie
Horsthemke, Bernhard
Lohmann, Dietmar R
Zeschnigk, Michael
author_sort Neumann, Lisa C
collection PubMed
description BACKGROUND: Uveal melanoma (UM) is a rare eye tumor. There are two classes of UM, which can be discriminated by the chromosome 3 status or global mRNA expression profile. Metastatic progression is predominantly originated from class II tumors or from tumors showing loss of an entire chromosome 3 (monosomy 3). We performed detailed EFS (embryonal Fyn-associated substrate) methylation analyses in UM, cultured uveal melanocytes and normal tissues, to explore the role of the differentially methylated EFS promoter region CpG island in tumor classification and metastatic progression. METHODS: EFS methylation was determined by direct sequencing of PCR products from bisulfite-treated DNA or by sequence analysis of individual cloned PCR products. The results were associated with clinical features of tumors and tumor-related death of patients. RESULTS: Analysis of 16 UM showed full methylation of the EFS CpG island in 8 (50%), no methylation in 5 (31%) and partial methylation in 3 (19%) tumors. Kaplan-Meier analysis revealed a higher risk of metastatic progression for tumors with EFS methylation (p = 0.02). This correlation was confirmed in an independent set of 24 randomly chosen tumors. Notably, only UM with EFS methylation gave rise to metastases. Real-time quantitative RT-PCR expression analysis revealed a significant inverse correlation of EFS mRNA expression with EFS methylation in UM. We further found that EFS methylation is tissue-specific with full methylation in peripheral blood cells, and no methylation in sperm, cultured primary fibroblasts and fetal muscle, kidney and brain. Adult brain samples, cultured melanocytes from the uveal tract, fetal liver and 3 of 4 buccal swab samples showed partial methylation. EFS methylation always affects both alleles in normal and tumor samples. CONCLUSIONS: Biallelic EFS methylation is likely to be the result of a site-directed methylation mechanism. Based on partial methylation as observed in cultured melanocytes we hypothesize that there might be methylated and unmethylated precursor cells located in the uveal tract. The EFS methylation of a UM may depend on which type of precursor cell the tumor originated from.
format Online
Article
Text
id pubmed-3175225
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31752252011-09-18 EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation Neumann, Lisa C Weinhäusel, Andreas Thomas, Stefanie Horsthemke, Bernhard Lohmann, Dietmar R Zeschnigk, Michael BMC Cancer Research Article BACKGROUND: Uveal melanoma (UM) is a rare eye tumor. There are two classes of UM, which can be discriminated by the chromosome 3 status or global mRNA expression profile. Metastatic progression is predominantly originated from class II tumors or from tumors showing loss of an entire chromosome 3 (monosomy 3). We performed detailed EFS (embryonal Fyn-associated substrate) methylation analyses in UM, cultured uveal melanocytes and normal tissues, to explore the role of the differentially methylated EFS promoter region CpG island in tumor classification and metastatic progression. METHODS: EFS methylation was determined by direct sequencing of PCR products from bisulfite-treated DNA or by sequence analysis of individual cloned PCR products. The results were associated with clinical features of tumors and tumor-related death of patients. RESULTS: Analysis of 16 UM showed full methylation of the EFS CpG island in 8 (50%), no methylation in 5 (31%) and partial methylation in 3 (19%) tumors. Kaplan-Meier analysis revealed a higher risk of metastatic progression for tumors with EFS methylation (p = 0.02). This correlation was confirmed in an independent set of 24 randomly chosen tumors. Notably, only UM with EFS methylation gave rise to metastases. Real-time quantitative RT-PCR expression analysis revealed a significant inverse correlation of EFS mRNA expression with EFS methylation in UM. We further found that EFS methylation is tissue-specific with full methylation in peripheral blood cells, and no methylation in sperm, cultured primary fibroblasts and fetal muscle, kidney and brain. Adult brain samples, cultured melanocytes from the uveal tract, fetal liver and 3 of 4 buccal swab samples showed partial methylation. EFS methylation always affects both alleles in normal and tumor samples. CONCLUSIONS: Biallelic EFS methylation is likely to be the result of a site-directed methylation mechanism. Based on partial methylation as observed in cultured melanocytes we hypothesize that there might be methylated and unmethylated precursor cells located in the uveal tract. The EFS methylation of a UM may depend on which type of precursor cell the tumor originated from. BioMed Central 2011-08-26 /pmc/articles/PMC3175225/ /pubmed/21871071 http://dx.doi.org/10.1186/1471-2407-11-380 Text en Copyright ©2011 Neumann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Neumann, Lisa C
Weinhäusel, Andreas
Thomas, Stefanie
Horsthemke, Bernhard
Lohmann, Dietmar R
Zeschnigk, Michael
EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation
title EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation
title_full EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation
title_fullStr EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation
title_full_unstemmed EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation
title_short EFS shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation
title_sort efs shows biallelic methylation in uveal melanoma with poor prognosis as well as tissue-specific methylation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3175225/
https://www.ncbi.nlm.nih.gov/pubmed/21871071
http://dx.doi.org/10.1186/1471-2407-11-380
work_keys_str_mv AT neumannlisac efsshowsbiallelicmethylationinuvealmelanomawithpoorprognosisaswellastissuespecificmethylation
AT weinhauselandreas efsshowsbiallelicmethylationinuvealmelanomawithpoorprognosisaswellastissuespecificmethylation
AT thomasstefanie efsshowsbiallelicmethylationinuvealmelanomawithpoorprognosisaswellastissuespecificmethylation
AT horsthemkebernhard efsshowsbiallelicmethylationinuvealmelanomawithpoorprognosisaswellastissuespecificmethylation
AT lohmanndietmarr efsshowsbiallelicmethylationinuvealmelanomawithpoorprognosisaswellastissuespecificmethylation
AT zeschnigkmichael efsshowsbiallelicmethylationinuvealmelanomawithpoorprognosisaswellastissuespecificmethylation